CYRDANAX 20mg / ml powder infusion solution medication leaflet

V03AF02 dexrazoxane • Various | All other therapeutic products | Detoxifying agents for antineoplastic treatment

Dexrazoxane is a medication used to protect against anthracycline-induced cardiotoxicity, a type of chemotherapy used in cancer treatment. It works by chelating iron ions, reducing the formation of free radicals that can damage the heart muscle.

The medication is administered intravenously, usually before anthracycline administration, under the supervision of an oncologist.

Side effects may include nausea, vomiting, decreased blood cell counts, or injection site reactions. In rare cases, severe allergic reactions may occur.

Patients should be closely monitored during treatment, and pregnant or breastfeeding women should consult a specialist before use.

General data about CYRDANAX 20mg / ml

Substance: dexrazoxane

Date of last drug list: 01-07-2020

Commercial code: W59811001

Concentration: 20mg / ml

Pharmaceutical form: powder infusion solution

Quantity: 1

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: PHARMASELECT INTERNATIONAL BETEILIGUNGS GMBH - AUSTRIA

Holder: PHARMASELECT INTERNATIONAL BETEILIGUNGS GMBH - AUSTRIA

Number: 11136/2018/01

Shelf life: after packaging for sale-2 years;after reconstitution-it is used immediately

Concentrations available for dexrazoxane

20mg/ml, 500mg